Z45 Stock Chart & Stats
€2.71
€0.22(8.12%)
At close: 4:00 PM EDT
€2.71
€0.22(8.12%)
Day’s Range― - ―
52-Week Range€2.52 - €7.98
Previous CloseN/A
Volume0.00
Average Volume (3M)246.00
Market Cap
€1.31B
Enterprise Value€2.53K
Total Cash (Recent Filing)€63.83M
Total Debt (Recent Filing)€1.46B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding390,431,500
10 Day Avg. Volume0
30 Day Avg. Volume246
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.46Price Target Upside27.84% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€532.00M
Bulls Say, Bears Say
Bulls Say
Scaled Revenue Base And Strong Gross MarginsAlvotech has built a materially larger revenue base over several years while maintaining ~60% gross margins. This durable top-line scale and high gross profitability underpin long-term unit economics, enable competitive pricing of biosimilars, and provide a foundation for margin recovery as manufacturing normalizes.
Broad Commercial Footprint And Market Share GainsMarket share traction for AVT02 and distribution in over 90 countries reflect durable commercial momentum and diversified revenue channels. Strong partner networks and geographic reach reduce single-market exposure, improve partner-led commercialization odds, and support recurring supply and licensing income over time.
Manufacturing Diversification With Fujifilm (U.S. Supply Planned)The Fujifilm manufacturing agreement materially strengthens capacity and supply resilience by adding U.S.-based production and technology transfer. This structural diversification reduces single-site execution risk, supports planned launches, and should improve long-term throughput and product margin sustainability once ramped.
Bears Say
Heavy Leverage And Negative EquityThe capital structure is stressed by large debt and persistent negative equity, constraining financial flexibility. High leverage elevates refinancing and covenant risk, limits strategic optionality, and amplifies downside if commercial ramps or regulatory timings slip, as interest and principal obligations remain substantial.
Persistent Operating And Free Cash Flow DeficitsConsistent negative OCF and FCF indicate the business is not self-funding and relies on external financing to sustain R&D and launches. Ongoing cash burn increases dilution or debt needs, raises refinancing risk ahead of key approvals, and constrains reinvestment capacity until positive cash generation is achieved.
Regulatory/manufacturing Disruptions Depressing MarginsInspection-driven production slowdowns and previous FDA CRLs materially reduced product margins and delayed launches. Such operational/regulatory overhangs create timing uncertainty for approvals and revenue, make margins lumpy, and necessitate remediation spend that can persistently impair near-term profitability and cash flow.
Alvotech News
Z45 FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was €2.52 and its highest was €7.98 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is €1.31B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is today.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -€0.078 earnings per share for the quarter, missing the consensus estimate of -€0.041 by -€0.037.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.05.
How many shares outstanding does Alvotech have?
Alvotech has 390,431,500 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -€0.078 in its last earnings report, missing expectations of -€0.041. Following the earnings report the stock price went down -11.726%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in DE:Z45
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€3.46 (27.84% Upside)
€3.46 (27.84% Upside)
Blogger Sentiment
Bullish
DE:Z45 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Z45 Company Deck
Z45 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.View all DE:Z45 earnings summariesZ45 Stock 12 Month Forecast
Average Price Target
€3.46
▲(27.84% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―